RAC 2.92% $1.94 race oncology ltd

RAC - Charts & Price Action, page-18465

  1. 2,715 Posts.
    lightbulb Created with Sketch. 3297
    The drug is yet to disappoint.

    It's possible that it's just a coincidence that Zan as a single agent obliterated the extramedullary disease of AML patients in Sheba 1.0 (given FTO is a driver of extramedullary disease).

    It's also possible that it's just a coincidence that there was no evidence of cardiotoxicity when Zan was used in combination with the known cardiotoxic Clofarabine.

    How many coincidences need occur before they are no longer a coincidence?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.